[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SMED Clinical Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100615952","phase-2-castration-with-abiraterone-250-mg-without-lhrh-analogs-or-blockers-in-patients-with-prostate-cancer-requiring-hormonal-intensification-multicenter-phase-2-100615952",false,"NCT07299292","Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed prostate adenocarcinoma.\n* Treated at Hospital Durand (Argentina) or Instituto Oncológico del Oriente Boliviano (Bolivia).\n* Indicated for hormonal intensification (high\u002Fvery high risk candidates for RT, or mHSPC for doublet\u002Ftriplet).\n* No prior ADT.\n* ECOG 0-2; adequate hepatic\u002Frenal function; K+ ≥3.5 mmol\u002FL; controlled BP.\n\nExclusion Criteria:\n\n* Hypersensitivity to ABI\u002Fprednisone; moderate-severe hepatic impairment; uncontrolled hypertension; refractory hypokalemia.\n* Concurrent therapy with strongly contraindicated\u002Finducing drugs affecting ABI levels without possibility of adjustment.","MALE","18 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","Hypothesis\n\nThe use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.",[25],"Prostate Cancer (Diagnosis)",[27,28,29,30],"prostate cancer","castration","abiraterone","hormonal intensification","RECRUITING","2025-12-09",{"date":34,"type":35},"2025-12-23","ACTUAL",{"date":37,"type":35},"2025-12-01",{"date":39,"type":19},"2027-03-30",{"name":41,"class":42},"SMED Clinical Research","OTHER",3,""]